Bio-Path Holdings, Inc. Stock News
$0.07
0.71%
Nasdaq,
Oct 09, 10:00 pm CET
Bio-Path Holdings, Inc. Stock News
Neutral
GlobeNewsWire
●
4 months ago
Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities
Neutral
GlobeNewsWire
●
5 months ago
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensiv...
Neutral
GlobeNewsWire
●
6 months ago
Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
